

SACRAMENTO VALLEY BIOLOGICALS TOUR

GROWER CHALLENGES & BIOLOGICAL PRODUCTS SOLUTIONS

BPIA ANNUAL MEETING
MARCH 31, 2025





Chamisal Creek Ranch

Chamisal Creek Ranch



University of California-Davis

University of California - Davis





CALIFORNIA DEPARTMENT OF
FOOD & AGRICULTURE



Scan to sign
up for IR-4's
Newsletter*:



The IR-4 Project

Pest management solutions for specialty crops and specialty uses



DunhamTrimmer®

Pro Farm Group

Pro Farm Group



Woodland Research & Development Center

Corteva Biologicals R&D

BPIA April 2025



Human beings are at
the center of concern
for sustainable
development.

They are entitled to a
healthy and productive
life in harmony with
nature.

-1992 Rio Declaration

How We Can Solve Farmer Challenges

Boost Performance

Activate the plant and its environment to maximize the harvest

Enhance the plants' ability to efficiently utilize soil, nutrients, water and sunlight.

Build Resilience

Empower crop vigor to withstand adversity and stress

Enable crops to thrive in the face of abiotic stresses and unfavorable weather

Protect Potential

Shield crops from pests and disease to ensure viability

Incorporate powerful and flexible solutions in crop protection programs



Safe Harbor Regarding Forward-Looking Statements

Forward-Looking Statements

This presentation contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like “plans,” “expects,” “will,” “anticipates,” “believes,” “intends,” “projects,” “estimates,” “outlook,” or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva’s (the “Company”) financial results or outlook; strategy for growth; product development; regulatory approvals; market position; capital allocation strategy; liquidity; environmental, social and governance (“ESG”) targets and initiatives; the anticipated benefits of acquisitions, restructuring actions, or cost savings initiatives; and the outcome of contingencies, such as litigation and environmental matters are forward-looking statements.

Forward-looking statements and other estimates are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements and other estimates also involve risks and uncertainties, many of which are beyond the Company’s control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on the Company’s business, results of operations and financial condition. Some of the important factors that could cause the Company’s actual results to differ materially from those projected in any such forward-looking statements include: (i) failure to successfully develop and commercialize the Company’s pipeline; (ii) failure to obtain or maintain the necessary regulatory approvals for some of the Company’s products; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of the Company’s biotechnology and other agricultural products; (iv) effect of changes in agricultural and related policies of governments and international organizations; (v) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (vi) effect of climate change and unpredictable seasonal and weather factors; (vii) failure to comply with competition and antitrust laws; (viii) effect of competition in the Company’s industry; (ix) competitor’s establishment of an intermediary platform for distribution of the Company’s products; (x) impact of the Company’s dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (xi) effect of volatility in the Company’s input costs; (xii) risk related to geopolitical and military conflict; (xiii) effect of industrial espionage and other disruptions to the Company’s supply chain, information technology or network systems; (xiv) risks related to environmental litigation and the indemnification obligations of legacy EIDP liabilities in connection with the separation; (xv) risks related to the Company’s global operations; (xvi) failure to effectively manage acquisitions, divestitures, alliances, restructurings, cost savings initiatives, and other portfolio actions; (xvii) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to the Company; (xviii) failure of the Company’s customers to pay their debts to the Company, including customer financing programs; (xix) increases in pension and other post-employment benefit plan funding obligations; (xx) capital markets sentiment towards ESG matters; (xxi) risks related to pandemics or epidemics; (xxii) the Company’s intellectual property rights or defend against intellectual property claims asserted by others; (xxiii) effect of counterfeit products; (xxiv) the Company’s dependence on intellectual property cross-license agreements; and (xxv) other risks related to the Separation of Corteva from DowDuPont.

Additionally, there may be other risks and uncertainties that the Company is unable to currently identify or that the Company does not currently expect to have a material impact on its business. Where, in any forward-looking statement or other estimate, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of the Company’s management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. The Company disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the “Risk Factors” section of the Company’s 2022 Annual Report on Form 10-K, as modified by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

List of treatment and FRAC group

Luna Sensation	Fluxipyr (21.4%) + diflufenican (21.4%)	Bayer	SDH (7), Qot (11)
Melita	Tetraconazole	Gowan	DMI (3)
Mentone	Eugenol 3.2% + geraniol 6.4% + limonene 6.4%	Sipcam Agro	Terpene (BM01)
Mixalis Prime	Fiducione (21.4%) + pydiflumetol (12.8%)	Syngenta	PP (12), SDH (7)
NIS	Adjuvant	N/A	N/A
Ondocor	adjuvant with Secondary Alcohol Ethoxylate	Oro-Agro	N/A
Shielder	Bacillus subtilis and sodium hydroxide	Oro-Agro	N/A
OSS	Adjuvant	N/A	N/A
OxDate 5.0	Hydrogen peroxide + peroxydicarbonate	BioDate	Qot (11), SDH (7)
Proline	Pyraclostrobin + boscalid	BASF	N/A
Prolied Verde	Semola de Lupinus albus doce (BLAD)	SymAgro	N/A
Prolio	Pyrazolone	Summit Agro	(50)
Quintec	Quinoxifen	Corteva	Aryloxyquinoline (13)
Raly	Mycolbutanol	Corteva	DMI (3)
Regalia	Extract of Reynoutria sachalinensis	Merrim Bio Innovations	Plant extract (P-05)
Ragev	Tea tree oil (40.6%) + diflufenican (20.3%)	Summit Agro	Terpene (BM02)
Rhyme	Flutriafol (22.7%)	FMC Corporation	DMI (3)
Rumeo	Proprietary	Wibbur Ellis	N/A
SA-0130310	Proprietary	Sipcam Agro	N/A
SA-050004	Proprietary	Sipcam Agro	N/A
Scale DFO	pyrimethanil + diflufenican	Bayer	AP (9)
Semirade AGO	Bacillus subtilis strain QST 713	Bayer	Microbial (44)
Steel	Surfactant	Helena Chemical Company	N/A
SPARORA	Proprietary	Wibbur Ellis	N/A
Sulfur DF	Sulfur (80%)	Wibbur Ellis	Inorganic (M-02)
Switch	Cyprodinil + fludioxonil	Syngenta	AP (9), PP (12)
Styl-Coat	Copolymer, polyether (100%)	Wibbur Ellis	N/A
Taado	Tebuconazole	Rotam Agrochemical	DMI (3)
Tanco	Cyflufenamid	Gowan	U-06
Trijan	Tetraconazole (13.8%)	FMC	DMI (3)
UC-78	Proprietary	BASF	SDH (7)
VSM-5-14	Proprietary	Corteva	N/A
Vivando	Metazolinone	BASF	(50)

Woodland Research & Development Center



Great Bear Vineyards

Great Bear Vineyards



SACRAMENTO VALLEY BIOLOGICALS TOUR

GROWER CHALLENGES & BIOLOGICAL PRODUCTS SOLUTIONS

BPIA ANNUAL MEETING
MARCH 31, 2025

